Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases

    loading  Checking for direct PDF access through Ovid


Clinical Question

Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non–small-cell lung cancer when highly active targeted therapies are available?

Clinical Application

Patients with EGFR-mutant or ALK-positive non–small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life.

Related Topics

    loading  Loading Related Articles